Additionally, although some studies have demonstrated a reduction in airway inflammation and infection with CFTR modulators, other studies have reported substantial residual inflammation and infection, at least to levels similar to those observed in NCFBE [12, 13, 81, 82]. This evidence concerns the gene CFTR and infection.